Streptococcus pneumoniae type 4 capsular polysaccharide antigen

Overview

Streptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

Indication

No indication information available.

Associated Conditions

Pneumococcal Infection

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age	2025/03/03	NCT06855160	Phase 3	Recruiting	GlaxoSmithKline
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age	2025/02/03	NCT06806137	Phase 3	Recruiting	GlaxoSmithKline
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age	2024/12/18	NCT06740630	Phase 3	Recruiting	GlaxoSmithKline
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age	2024/11/18	NCT06693895	Phase 3	Recruiting	GlaxoSmithKline

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Prevenar 13	Pfizer Europe MA EEIG,Boulevard de la Plaine 17,1050 Bruxelles,Belgium	Authorised	12/9/2009
Synflorix	GlaxoSmithKline Biologicals S.A.,Rue de l'Institut, 89,B-1330 Rixensart,Belgium	Authorised	3/29/2009
Prevenar 20 (previously Apexxnar)	Pfizer Europe MA EEIG,Boulevard de la Plaine 17,1050 Bruxelles,Belgium	Authorised	2/14/2022

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML	Pfizer Ireland Pharmaceuticals	SIN16648P	INJECTION, SUSPENSION	2.2 μg/0.5ml	11/30/2022
Prevenar 13 Suspension For Injection	Pfizer Ireland Pharmaceuticals	SIN13824P	INJECTION, SUSPENSION	2.2mcg	7/2/2010

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

FDA Approves Capvaxive, First Adult-Specific 21-Valent Pneumococcal Vaccine

5 months ago

MSD's Capvaxive, a groundbreaking 21-valent pneumococcal vaccine, receives FDA approval as the first shot specifically designed for adults, covering 84% of invasive pneumococcal disease cases in those over 50.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access